Healthcare / BiotechnologyNasdaqCM
$11.04
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-15.8M · quality 51.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
7/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$55M
P/E
N/A
•EV/EBITDA
N/A
•ROE
87.8%
↑Gross Margin
N/A
•Debt/Equity
N/A
•Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
—
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-12.5M · FCF —
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Net Income | $-12.5M | $-12.5M | $-10.8M | $-22.5M | $-28.0M | $-30.2M | $-16.2M |
| EPS | -2.93 | -2.93 | -2.86 | -6.54 | -0.83 | -1.16 | — |
| Cash Flow | |||||||
| Free Cash Flow | — | — | — | $-15.8M | $-19.1M | $-13.1M | $-8.4M |
| Returns | |||||||
| ROE | 87.8% | 87.8% | 55.1% | 124.4% | 6975.1% | -127.1% | 30.1% |
| Growth & Yield | |||||||
| EPS Growth | -2.4% | -2.4% | 56.3% | -688.0% | 28.4% | — | — |
Returns (%)
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.